It has been reported that RAS mutations were more likely to be enriched in high-risk ALL group, including patients with early relapse (H-, K-, and N- RAS mutations) and with central nervous system (CNS) involvement (NRAS and KRAS mutations) (Reshmi et al., 2017; Takashima et al., 2018). The gene discussed is KRAS; the disease is acute lymphoblastic leukemia.